Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

Daud, Adil; Loo, Kimberly; Pauli, Mariela; Rodriguez, Robert Sanchez; Sandoval, Priscila Muñoz; Taravati, Keyon; Tsai, Katy K.; Nosrati, Adi; Nardo, Lorenzo; Alvarado, Michael; Algazi, Alain P.; Pampaloni, Miguel Hernandez; Lobach, Iryna; Hwang, Jimmy J.; Pierce, Robert H.; Gratz, Iris K.; Krummel, Matthew F.; Rosenblum, Michael D.

doi:10.1172/jci87324

Cited by 458 publications

(386 citation statements)

References 21 publications

Supporting

Mentioning

347

Contrasting

Order By: Relevance

“…While the relative abundance of tumor-infiltrating peCTLs correlates with response to anti-PD-1 monotherapy (18), it is currently unknown whether this metric predicts response to ipilimumab/nivolumab combination therapy. Thus, we quantified peCTLs and ORRs by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria (26) to ipilimumab/nivolumab combination therapy (n = 29) and compared these with anti-PD-1 monotherapy (n = 64) (Figure 3).…”

Section: Resultsmentioning

confidence: 99%

“…We have recently shown that the fraction of partially exhausted cytotoxic T lymphocytes (peCTLs, tumor-infiltrating CD8 + T cells expressing high levels of cytotoxic T lymphocyte-associated antigen 4 and PD-1) strongly correlates with response to anti-PD-1 monotherapy (18). Functionally, these cells may contain tumor-antigen-specific T cells (19,20), and they demonstrate a partially exhausted phenotype which is hypothesized to be activated by treatment with anti-PD-1 (18,21).…”

Section: Introductionmentioning

confidence: 99%

“…Functionally, these cells may contain tumor-antigen-specific T cells (19,20), and they demonstrate a partially exhausted phenotype which is hypothesized to be activated by treatment with anti-PD-1 (18,21). Here, we examine how the relative abundance of peCTLs correlates with specific host factors, as well as response to immune checkpoint monotherapy and combination therapy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy

Loo¹,

Tsai²,

Mahuron

et al. 2017

JCI Insight

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy

Loo¹,

Tsai²,

Mahuron

et al. 2017

JCI Insight

Self Cite

View full text Add to dashboard Cite

“…Meanwhile, clinical activity of anti-PD-L1 antibodies has been observed in various malignancies, such as melanoma, non-small cell lung cancer, squamous head and neck cancer, microsatellite-unstable colorectal cancer, and other types of cancers [55][56][57][58]. A predictive role of PD-L1 expression and TIL (tumor infiltrating lymphocytes) has been found in lung cancer patients receiving anti-PD-1/PD-L1 immunotherapy and could be used to improve clinical interpretations [59].…”

Section: Role Of Pd-l1 In Efficacy Of Treatmentmentioning

confidence: 99%

“…Mazanet et al reported that the promoter region of CD274 gene consisted several elements responded to IFN-γ, which was necessary for upregulation of PD-L1 expression mediated by IFN-γ [64]. PD-L1 exerts a role as a type I transmembrane protein and contains four domains [56]. They are Ig (immunoglobulin) V-like domain, Ig C-like domain, and hydrophobic transmembrane domain, as well as cytoplasmic domains, encoded by single exon sequences [62].…”

Section: Structure Of Pd-l1mentioning

confidence: 99%

The function and regulation of PD-L1 in immunotherapy

Guo¹,

Lin²,

Kwok³

2017

ADMET DMPK

View full text Add to dashboard Cite

PD-L1, also known as B7-H1, is a type I transmembrane protein, which is expressed in different kinds of tumor cells. It is correlated with poor clinical outcome of patients with various types of tumors. PD-L1 can regulate tumor microenvironment or tumor related immune response through suppressing T cell or NK cell mediated immune response. PD-L1 expression is regulated by various cytokines, such as LPS, GM-CSF, IL-4, TGF-β, TNF-α. PD-1 and PD-L1 are the members of B7 and CD28 superfamily, respectively. The B7/CD28 interaction plays a central role in immune tolerance. PD-L1 can bind to PD-1, which leads to the suppression of lymphocyte activation and apoptosis of lymphocytes. Anti-PD-L1 therapy is one of the immunotherapies to treat cancer (especially solid tumor). PD-L1 expression may be associated with efficacy

show abstract

Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases

et al. 2021

View full text Add to dashboard Cite

Key Points Question Is immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 (PD-1/PD-L1) associated with the presence of liver metastasis at the time of therapy and outcomes among patients with treatment-resistant microsatellite stable (MSS) metastatic colorectal cancer? Findings This cohort study included 95 patients with MSS metastatic colorectal cancer. Patients without liver metastases had a significantly superior objective response rate (19.5% vs 0) and median progression-free survival (4.0 vs 1.5 months) compared with patients with liver metastases; multivariate analysis revealed that the presence of liver metastases was an independent prognostic factor associated with poor outcome of PD-1/PD-L1 therapy. Meaning This cohort study suggests that PD-1/PD-L1 inhibitors should be reinvestigated in prospective trials in patients with MSS metastatic colorectal cancer without liver involvement.

show abstract

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

Cited by 458 publications

References 21 publications

Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy

Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy

The function and regulation of PD-L1 in immunotherapy

Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases

Contact Info

Product

Resources

About